Bay Area's Arcus Biosciences Scores $107M, Initiates Two Clinical Trials Post author:Sam Post published:November 12, 2017 Post category:BioPharma Now totaling $227M, Arcus Biosciences announced it had closed a $107M Series C financing. Source: BioSpace You Might Also Like Prolacta Bioscience To Present At The 2017 Conference On February 22, 2017 February 21, 2017 FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer January 11, 2018 Bay Area's Dynavax Quietly Shops Around Its Almost-Approved Hep B Vaccine October 1, 2017